largely on the promise of Nurtec ODT, which made almost $1.4 billion in sales in 2023 and has been predicted to have reached more than $1.8 billion last year. The drug is approved both to treat ...

From its Primary Care segment, I highlight Nurtec ODT/Vydura (rimegepant), a medication for the treatment of various types of migraines, which partially minimized the decline in sales of the RSV ...

Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Q4 2024 Earnings Call Transcript March 6, 2025 Phathom Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...

This provides non-English speaking patients with rapid, accurate, and legally compliant discharge instructions in their preferred language ...

A Baton Rouge paramedic who allegedly called in prescriptions while pretending to be a doctor has taken a plea deal.

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a study approval ...

Migraine disrupts daily life with invisible neurological pain, causing physical, emotional, and cognitive struggles that go ...

The lawyers of Dean Wickliffe say he is on hunger strike at the Spring Hill Corrections Facility after alleging he was beaten ...

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that ... ITI-1284-ODT-SL in Phase 2 ...